Coronary Vasomotor Abnormalities in Insulin-Resistant Individuals

  1. Manuel J. Quiñones, MD;
  2. Miguel Hernandez-Pampaloni, MD, PhD;
  3. Heinrich Schelbert, MD, PhD;
  4. Isabel Bulnes-Enriquez, MD;
  5. Xochitl Jimenez, MD;
  6. Gustavo Hernandez, MD;
  7. Roxana De La Rosa, BS;
  8. Yun Chon, PhD;
  9. Huiying Yang, MD, PhD;
  10. Susanne B. Nicholas, MD, PhD;
  11. Tamara Modilevsky, MD;
  12. Katherine Yu, MD;
  13. Katja Van Herle, MD;
  14. Lawrence W. Castellani, PhD;
  15. Robert Elashoff, PhD; and
  16. Willa A. Hsueh, MD
  1. From University of California, Los Angeles, Los Angeles; Cedars-Sinai Medical Center, Los Angeles; and Olive View–University of California, Los Angeles Medical Center, Sylmar, California.

    Abstract

    Background: Insulin resistance is a metabolic spectrum that progresses from hyperinsulinemia to the metabolic syndrome, impaired glucose tolerance, and finally type 2 diabetes mellitus. It is unclear when vascular abnormalities begin in this spectrum of metabolic effects.

    Objective: To evaluate the association of insulin resistance with the presence and reversibility of coronary vasomotor abnormalities in young adults at low cardiovascular risk.

    Design: Cross-sectional study followed by prospective, open-label treatment study.

    Setting: University hospital.

    Patients: 50 insulin-resistant and 22 insulin-sensitive, age-matched Mexican-American participants without glucose intolerance or traditional risk factors for or evidence of coronary artery disease.

    Intervention: 3 months of thiazolidinedione therapy for 25 insulin-resistant patients.

    Measurements: Glucose infusion rate in response to insulin infusion was used to define insulin resistance (glucose infusion rate ≤ 4.00 mg/kg of body weight per minute [range, 0.90 to 3.96 mg/kg per minute]) and insulin sensitivity (glucose infusion rate ≥ 7.50 mg/kg per minute [range, 7.52 to 13.92 mg/kg per minute]). Myocardial blood flow was measured by using positron emission tomography at rest, during cold pressor test (largely endothelium-dependent), and after dipyridamole administration (largely vascular smooth muscle–dependent).

    Results: Myocardial blood flow responses to dipyridamole were similar in the insulin-sensitive and insulin-resistant groups. However, myocardial blood flow response to cold pressor test increased by 47.6% from resting values in insulin-sensitive patients and by 14.4% in insulin-resistant patients. During thiazolidinedione therapy in a subgroup of insulin-resistant patients, insulin sensitivity improved, fasting plasma insulin levels decreased, and myocardial blood flow responses to cold pressor test normalized.

    Limitations: The study was not randomized, and it included only 1 ethnic group.

    Conclusions: Insulin-resistant patients who do not have hypercholesterolemia or hypertension and do not smoke manifest coronary vasomotor abnormalities. Insulin-sensitizing thiazolidinedione therapy normalized these abnormalities. These results suggest an association between insulin resistance and abnormal coronary vasomotor function, a relationship that requires confirmation in larger studies.

    Article and Author Information

    • Acknowledgments: The authors thank Drs. Alan Fogelman and Jerome Rotter for their critical review of this manuscript.

    • Grant Support: By National Institutes of Health grants HL33177 and 5PO1HL6003.

    • Potential Financial Conflicts of Interest:Consultancies: M.J. Quiñones (GlaxoSmithKline), W.A. Hsueh (Merck, GlaxoSmithKline, Novartis); Honoraria: M.J. Quiñones (GlaxoSmithKline), K. Van Herle (Novartis, GlaxoSmithKline, Takeda-Lilly); Grants received: M.J. Quiñones (GlaxoSmithKline), W.A. Hsueh (Merck, GlaxoSmithKline, Novartis, Takeda).

    • Requests for Single Reprints: Willa A. Hsueh, MD, Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at University of California, Los Angeles, 900 Veteran Avenue, Suite 24-130, Los Angeles, CA 90095; e-mail, whsueh{at}mednet.ucla.edu.

    • Current Author Addresses: Drs. Quiñones, Bulnes-Enriquez, Jimenez, Van Herle, and Hsueh and Ms. De La Rosa: Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at University of California, Los Angeles, 900 Veteran Avenue, Suite 24-130, Los Angeles, CA 90095.

    • Dr. Hernandez-Pampaloni: Department of Radiology, Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104.

    • Dr. Schelbert: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, B2-085J, CHS Box 95648, 650 Charles E. Young Drive South, Los Angeles, CA 90095-6948.

    • Drs. Hernandez, Modilevsky, and Yu: Department of Medicine, Olive View–University of California, Los Angeles Medical Center, Room 2B182, 14445 Olive View Drive, Sylmar, CA 91342.

    • Drs. Chon and Elashoff: Department of Biomathematics, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1766.

    • Dr. Yang: Division of Medical Genetics, Departments of Pediatrics, Steven Spielberg Pediatric Research Center, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.

    • Dr. Nicholas: Division of Nephrology and Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at University of California, Los Angeles, 900 Veteran Avenue, Suite 24-130, Los Angeles, CA 90095.

    • Dr. Castellani: Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, 547-123 CHS, Los Angeles, CA 90095.

    • Author Contributions: Conception and design: M.J. Quiñones, W.A. Hsueh.

    • Analysis and interpretation of the data: M.J. Quiñones, M. Hernandez-Pampaloni, H. Schelbert, Y. Chon, H. Yang, R. Elashoff, W.A. Hsueh.

    • Drafting of the article: M.J. Quiñones, W.A. Hsueh.

    • Critical revision of the article for important intellectual content: M.J. Quiñones, M. Hernandez-Pampaloni, H. Schelbert, Y. Chon, S.B. Nicholas, R. Elashoff, W.A. Hsueh.

    • Final approval of the article: M.J. Quiñones, M. Hernandez-Pampaloni, H. Schelbert, W.A. Hsueh.

    • Provision of study materials or patients: M.J. Quiñones, I. Bulnes-Enriquez, X. Jimenez, G. Hernandez, R. De La Rosa, T. Modilevsky, K. Yu, K. Van Herle, W.A. Hsueh.

    • Statistical expertise: M.J. Quiñones, Y. Chon, H. Yang, R. Elashoff, W.A. Hsueh.

    • Obtaining of funding: W.A. Hsueh.

    • Administrative, technical, or logistic support: M.J. Quiñones, M. Hernandez-Pampaloni, I. Bulnes-Enriquez, X. Jimenez, G. Hernandez, R. De La Rosa, S.B. Nicholas, K. Van Herle, L.W. Castellani, W.A. Hsueh.

    • Collection and assembly of data: M.J. Quiñones, M. Hernandez-Pampaloni, I. Bulnes-Enriquez, X. Jimenez, G. Hernandez, R. De La Rosa, Y. Chon, H. Yang, L.W. Castellani, W.A. Hsueh.

    Related Article

    • Summaries for Patients: Insulin Resistance Is Associated with Abnormalities of Coronary Arteries in People without Other Cardiac Risk Factors Ann Intern Med May 4, 2004 140:I-32
    | Table of Contents

    This Article

    1. Ann Intern Med May 4, 2004 vol. 140 no. 9 700-708
    1. » AbstractFREE
    2. Full Text
    3. Full Text (PDF)FREE
    4. Related Article

    Comments

    1. Submit a comment
    2. No comments published

    Share

    Current Issue

    1. February 7, 2012, 156 (3)
    1. Alert me to current issues
    Most Read Most Read
    Most Commented Most Commented On
    Annals in the News Annals in the News
    Clinical Trials Clinical Trials
    Comparative Effectiveness Comparative Effectiveness
    Hospital Medicine Hospital Medicine
    • Advertisement
    • Advertisement